DA Davidson Boosts UiPath (NYSE:PATH) Price Target to $24.00

UiPath (NYSE:PATH) had its target price raised by DA Davidson from $20.00 to $24.00 in a research note issued to investors on Thursday morning, Benzinga reports. They currently have a neutral rating on the healthcare company’s stock.

A number of other analysts have also weighed in on the stock. Scotiabank raised their price objective on shares of UiPath from $29.00 to $30.00 and gave the company a sector perform rating in a research note on Thursday. BMO Capital Markets raised their price target on shares of UiPath from $24.00 to $28.00 and gave the company a market perform rating in a research report on Thursday. Morgan Stanley boosted their price objective on shares of UiPath from $17.00 to $25.00 and gave the stock an equal weight rating in a report on Thursday. Evercore ISI increased their target price on UiPath from $24.00 to $27.00 and gave the company an in-line rating in a research note on Thursday. Finally, Royal Bank of Canada boosted their price target on UiPath from $27.00 to $29.00 and gave the stock a sector perform rating in a research note on Thursday. Nine research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, UiPath currently has a consensus rating of Hold and an average target price of $27.13.

UiPath Price Performance

NYSE:PATH traded up $0.32 during mid-day trading on Thursday, hitting $23.07. 9,842,354 shares of the company’s stock were exchanged, compared to its average volume of 10,074,664. The business has a fifty day moving average price of $23.52 and a 200 day moving average price of $20.70. UiPath has a one year low of $12.38 and a one year high of $27.87. The company has a market cap of $13.06 billion, a PE ratio of -135.46 and a beta of 0.97.

Insider Buying and Selling at UiPath

In related news, CFO Ashim Gupta sold 125,000 shares of the firm’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $22.59, for a total value of $2,823,750.00. Following the transaction, the chief financial officer now directly owns 858,148 shares of the company’s stock, valued at approximately $19,385,563.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CFO Ashim Gupta sold 125,000 shares of the business’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $22.59, for a total transaction of $2,823,750.00. Following the completion of the transaction, the chief financial officer now directly owns 858,148 shares in the company, valued at approximately $19,385,563.32. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Rich Wong sold 200,000 shares of the firm’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the sale, the director now owns 429,418 shares in the company, valued at approximately $9,928,144.16. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 411,000 shares of company stock valued at $9,418,670. Insiders own 31.03% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Intech Investment Management LLC grew its holdings in UiPath by 3.1% during the 4th quarter. Intech Investment Management LLC now owns 14,324 shares of the healthcare company’s stock valued at $356,000 after buying an additional 426 shares in the last quarter. 180 Wealth Advisors LLC increased its holdings in UiPath by 0.3% in the 4th quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company’s stock valued at $4,497,000 after acquiring an additional 492 shares during the last quarter. Bleakley Financial Group LLC lifted its stake in UiPath by 4.9% in the 4th quarter. Bleakley Financial Group LLC now owns 12,691 shares of the healthcare company’s stock worth $315,000 after purchasing an additional 598 shares in the last quarter. Simplicity Solutions LLC boosted its holdings in shares of UiPath by 4.9% during the 4th quarter. Simplicity Solutions LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after purchasing an additional 598 shares during the last quarter. Finally, Creative Planning grew its position in shares of UiPath by 7.0% during the second quarter. Creative Planning now owns 10,163 shares of the healthcare company’s stock valued at $185,000 after purchasing an additional 666 shares in the last quarter. Institutional investors own 59.04% of the company’s stock.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.